If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
This Amendment No. 1 to Schedule 13D (this "Amendment No. 1") amends and supplements the Schedule 13D originally filed with the Securities and Exchange Commission on April 17, 2026 (the "Schedule 13D") relating to the ordinary shares, nominal value (euro)0.01 per share (the "Ordinary Shares"), of Davion Healthcare plc, an Irish public limited company (the "Issuer"). Capitalized terms used but not otherwise defined herein have the meanings ascribed to such terms in the Schedule 13D. Except as specifically amended and supplemented by this Amendment No. 1, the Schedule 13D remains unchanged.


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


 
JACK HARRY KAYE
 
Signature:/s/ Jack Harry Kaye
Name/Title:Jack Kaye, Chief Executive Officer, Davion Healthcare Plc
Date:08/11/2026
 
RALLINSON CORP
 
Signature:/s/ Jack Kaye
Name/Title:Jack Kaye, beneficial owner of Rallinson Corp
Date:08/11/2026
 
RALLINSON LTD
 
Signature:/s/ Jack Kaye
Name/Title:Jack Kaye, beneficial owner of Rallinson Ltd
Date:08/11/2026